AB Science: CHMP negative opinion on appeal for conditional authorization of Masitinib in second-line treatment of GIST
March 20, 2014 14:40 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 20 March 2014, 7:00 pm AB Science...
AB Science : Initiation d'une nouvelle étude de phase 3 avec le masitinib dans le cancer de la prostate suite à des résultats encourageants de survie en phase 2
February 20, 2014 11:59 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 20 Février 2014, 17h45 AB Science...
AB Science: initiation of a new phase 3 study with masitinib in Prostate Cancer, following encouraging survival results obtained in a phase 2 study
February 20, 2014 11:59 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 20 February 2014, 5:45 pm AB Science...
AB Science: Turnover up 56% compared to 2012 fourth quarter
February 14, 2014 12:01 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 14 February 2014, 5.45 pm Quarterly...
AB Science : Chiffre d'affaires en hausse de 56% par rapport au 4ème trimestre 2012
February 14, 2014 12:01 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 14 février 2014, 17h45 Information...
AB Science: AB Science announces CHMP has adopted a negative opinion for the conditional approval of Masitinib in the treatment of pancreatic cancer
January 23, 2014 12:13 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 23 January 2014, 5:45 pm AB Science...
AB Science : AB Science annonce que le CHMP a adopté un avis négatif pour l'enregistrement conditionnel du masitinib dans le traitement du cancer du pancréas
January 23, 2014 12:13 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 23 Janvier 2014, 17h45...
AB Science : Information mensuelle relative au nombre total de droits de vote et d'actions
December 05, 2013 13:00 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
AB SCIENCE S.A.Société Anonyme au capital de 326...
AB Science announces initiation of a new phase 3 study in oncology with masitinib in patients with metastatic colorectal cancer
December 02, 2013 12:32 ET
|
AB Science
PARIS, Dec. 2, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors...
AB Science: initiation of a new phase 3 study in oncology with masitinib in patients with metastatic colorectal cancer
December 02, 2013 12:00 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 2 December 2013, 6:00 pm AB Science...